Adeno-Associated Virus-Mediated Gene Therapy - Advances, Immune Challenges, and Research Innovations

Why It Matters

The FDA’s focused research and evolving regulatory framework aim to reduce immune-related toxicities and improve durable efficacy, accelerating safer commercialization of AAV therapies for rare and systemic diseases. Better capsid design, deimmunization methods, and CQA guidance could lower clinical risk, streamline approvals, and broaden patient access to gene therapies.

Summary

At FDA Grand Rounds, Dr. Ronit Mazur of CBER reviewed advances and persistent immunological challenges in adeno-associated virus (AAV)–mediated gene therapy, outlining how AAV’s favorable safety and durability have driven a surge in FDA approvals since 2017. She summarized AAV biology and contrasted viral vector platforms, traced the regulatory trajectory from the first IND in 1995 to multiple recent BLAs, and highlighted clinical setbacks tied to immune responses. Dr. Mazur then detailed CBER laboratory research on capsid engineering, deimmunization strategies, sex-based immune differences, and new critical quality attributes (CQAs) that influence safety and immunogenicity. Her presentation emphasized translational tools and assays the FDA is developing to predict and mitigate immune reactions and to inform manufacturing and regulatory review.

Original Description

Join Dr. Ronit Mazor from the FDA's Center for Biologics Evaluation and Research (CBER) as she presents groundbreaking research on adeno-associated virus (AAV) gene therapy. This comprehensive presentation covers the latest regulatory milestones, immunological challenges, and cutting-edge solutions being developed in CBER's research labs.

Key Topics Covered:

✅ AAV gene therapy fundamentals and viral vector mechanisms

✅ Regulatory landscape: From Luxturna to Zolgensma and beyond

✅ Immunogenicity challenges and mitigation strategies

✅ Rational capsid engineering and deimmunization approaches

✅ Sex-based differences in immune responses to AAV

✅ Post-translational modifications (deamidation) and product quality

✅ CRISPR-Cas9 delivery and genome editing applications

✅ E-MAP computational tool for designing safer gene therapies

Dr. Mazor shares insights from multiple published studies in Nature Biomedical Engineering, Nature Communications, and other leading journals, demonstrating how FDA research directly supports regulatory science and improves patient outcomes.

Perfect for: Gene therapy researchers, regulatory professionals, clinicians, pharmaceutical developers, and anyone interested in cutting-edge biotechnology and precision medicine.